Higher Dosage Form of Candesarten Cilexetil for Hypertension Approved in Europe
Main Category: HypertensionArticle Date: 16 Aug 2004 - 11:00 PDT
| Patient / Public: | ![]() |
3.63 (8 votes) |
| Healthcare Prof: | ![]() |
|
| Article Opinions: | 1 posts |
Takeda Pharmaceutical Company Limited announced today that on August 10, 2004, its wholly-owned subsidiary, Takeda Europe Research & Development Centre Ltd received an approval for 32mg tablet of candesartan cilexetil (Blopress®, Amias®, Kenzen®) for hypertension use under the European Mutual Recognition Procedures.
The approval covers 14 countries of European Union including The United Kingdom, Germany, Austria, Italy, Spain, Portugal and Ireland.
This 32mg dose once daily will offer an additional treatment option of hypertension specifically for patients whose blood pressure are not controlled adequately with the dosages of 8mg and 16mg of candesartan.
This higher dose of 32mg was the target dose of CHARM study, in which candesartan improved the mortality of CHF and cardiovascular symptoms associated with CHF. Based on the outcome of this large scale study, the CHF indication is being reviewed by the European regulatory authorities.
CHARM study was sponsored and conducted by AstraZeneca.
Candesartan cilexetil was discovered and originally synthesized by Takeda, and it offers a new type of treatment options by its mechanism of action to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II. The product was jointly developed with AstraZeneca. Candesartan cilexetil is marketed worldwide under the brand names Blopress®, Amias®, Kenzen® by Takeda and Atacand® by AstraZeneca in around 70 countries.
About Takeda Pharmaceutical Company Limited
Takeda, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.
Visit our hypertension section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/12112.php>
APA
http://www.medicalnewstoday.com/releases/12112.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Candesartin and liver function
posted by Ron Sams on 15 Apr 2005 at 1:30 amI have been taking 16mg daily and during my annual executive medical the blood test results have indicated a higher liver function status of ALT 132 and Gamma GT of 56. This has been consistently the case since I first started taking the drug. Is this common and do we believe this is detrimental to the liver long-term?
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




